ABO-101
Small molecule
ABO-101 is one of 5 small molecule programs targeting Primary Hyperoxaluria Type 1. It is currently in development.
1
Indications
2
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Primary Hyperoxaluria Type 1
#DrugCompanyPhaseTrials
1Diacomit
BBiocodex
Phase 3
Oxlumo
Alnylam PharmaceuticalsPhase 2
DCR-PHXC
DDicerna Pharmaceuticals, Inc., a Novo Nordisk company
Phase 2
Rivfloza
Novo NordiskPreclinical
ABO-101
AArbor Biotechnologies
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ABO-101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- AArbor Biotechnologies